Research programme: brain injury therapies - Edge Therapeutics

Drug Profile

Research programme: brain injury therapies - Edge Therapeutics

Alternative Names: EG-1960; EG-1961; EG-1964; NimoGel™

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Edge Therapeutics
  • Developer Edge Therapeutics; University of Toronto
  • Class Dihydropyridines; Nicotinic-acids
  • Mechanism of Action Calcium channel antagonists; Chymotrypsin inhibitors; Kallikrein inhibitors; Plasmin inhibitors; Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cerebral ischaemia; Subdural haematoma
  • Research Brain injuries; Neurological disorders

Most Recent Events

  • 22 Mar 2017 Edge Therapeutics announces intention to submit IND for EG 1964 to US FDA for Cerebral ischaemia in 2018 (EdgeTherapeutics 10-K, March 2017)
  • 09 Sep 2016 Early research in Neurological disorders in USA before September 2016 (Edge Therapeutics, September 2016)
  • 18 Nov 2014 Edge Therapeutics enters into a collaboration with St. Michael's Hospital, an affiliate of the University of Toronto, to discover therapeutics for the treatment of a variety of acute neurological conditions resulting from neurovascular instability
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top